15 March 2018 - HAS has posted the agenda for the next scheduled TC meeting.

The Transparency Commission will consider the reimbursement of:

• Lesinurad (Zurampic)
  
• Misoprostol (Angusta)
  
• Evolocumab (Repatha)
  
• Avelumab (Bavencio)
  
• Fluticasone furoate with vilanterol trifenatate and umeclidinium bromide (Elebrato Ellipta, Trelegy Ellipta)
  

Read TC agenda [French]